Table 2.
Relative PS error (%).
| Patient | Tt > 0 s | Tt < 25 s | 25 s ≤ Tt < 40 s | Tt > 40 s |
|---|---|---|---|---|
| HL 1 | 17.00 | 13.00 | 16.00 | 6.40 (1.3) |
| HL 2 | 29.00 | 65.00 | 0.00 | 0.00 |
| HL 3 | 6.10 | 12.00 | 0.34 | 0.00 |
| HL 4 | 36.00 | 61.00 | 24.00 | 7.70 (0.96) |
| HL 5 | 36.00 | 49.00 | 1.20 | 0.78 |
| HL 6 | 5.40 | 3.10 | 1.60 | 1.10 (0.38) |
| HL 7 | 15.00 | 18.00 | 1.30 | 0.00 |
| LC 1 | 3.30 | 5.20 | 0.00 | 0.00 |
| LC 2 | 8.40 | 14.00 | 1.20 | 0.00 |
| LC 3 | 18.00 | 1.50 | 0.00 | 0.00 |
| RCC 1 | 14.00 | 24.00 | 0.00 | 0.00 |
| RCC 2 | 14.00 | 20.00 | 0.45 | 0.00 |
| RCC 3 | 4.30 | 73.00 | 0.00 | 0.00 |
| RCC 4 | 19.00 | 15.00 | 6.00 | 0.00 |
For each patient (column 1), the standard deviation of PS over the tumour ROI/the truncation interval (expressed as a % of the PS mean) is given for each of the truncation intervals (column 2) and in subsequent truncation time (Tt) intervals (columns 3, 4, and 5). For necrotic lymphomas (i.e., HL1, HL4, and HL6) we also list in parenthesis the value shifting the last Tt cut at 50 sec.
HL: Hodgkin lymphoma; LC: lung cancer; RCC: renal cell carcinoma.